Eli Lilly and Company $LLY Shares Acquired by Bensler LLC

Bensler LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 5.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 19,681 shares of the company’s stock after acquiring an additional 1,014 shares during the period. Eli Lilly and Company comprises approximately 2.1% of Bensler LLC’s investment portfolio, making the stock its 11th largest position. Bensler LLC’s holdings in Eli Lilly and Company were worth $21,151,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Maryland Capital Advisors Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter valued at $25,000. Vermillion & White Wealth Management Group LLC grew its holdings in Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after purchasing an additional 16 shares in the last quarter. 10Elms LLP grew its holdings in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 10 shares in the last quarter. Miller Global Investments LLC acquired a new stake in Eli Lilly and Company during the 4th quarter valued at $33,000. Finally, Hopwood Financial Services Inc. grew its holdings in Eli Lilly and Company by 113.6% during the 3rd quarter. Hopwood Financial Services Inc. now owns 47 shares of the company’s stock valued at $36,000 after purchasing an additional 25 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Rothschild & Co Redburn raised its price target on Eli Lilly to $900 from $880, signaling continued confidence in the company’s long-term value despite the target still sitting below the recent share price. MarketScreener
• Positive Sentiment: Multiple reports highlighted strong demand for Lilly’s GLP-1 medicines, including Mounjaro, with first-quarter sales described as a major driver of revenue growth and a key reason investors remain optimistic about future earnings. Motley Fool
• Positive Sentiment: Reuters reported that early weight-loss pill data is boosting Lilly and Novo Nordisk by raising hopes the market could expand beyond injections to millions more patients, which could support a larger long-term revenue opportunity. Reuters
• Positive Sentiment: Lilly announced an additional $4.5 billion investment in Indiana manufacturing sites, reinforcing confidence in its ability to meet future demand for weight-loss and other therapies while expanding U.S. production capacity. Benzinga
• Neutral Sentiment: Several commentary pieces continued to frame Lilly as a high-quality growth stock, but these were largely reiterations of the bullish long-term thesis rather than fresh catalysts. Zacks
• Neutral Sentiment: Articles about shareholder support for the board and broader analyst upgrades suggest stable governance and sentiment, but they do not appear to be major standalone trading catalysts. TipRanks
• Negative Sentiment: One article noted that Eli Lilly’s valuation remains rich and that some investors see more upside in competitors, which can limit enthusiasm even when fundamentals are strong. Motley Fool

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $948.01 on Monday. The firm has a market cap of $892.78 billion, a P/E ratio of 33.68, a P/E/G ratio of 1.03 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The firm has a fifty day moving average of $943.90 and a two-hundred day moving average of $990.90.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period last year, the firm posted $3.34 EPS. The company’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. TD Cowen raised their price target on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a report on Thursday, January 29th. Morgan Stanley reissued an “overweight” rating and set a $1,344.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 1st. Bank of America decreased their price objective on shares of Eli Lilly and Company from $1,294.00 to $1,133.00 and set a “buy” rating for the company in a report on Friday, May 1st. UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Finally, Daiwa Securities Group raised their price objective on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,218.33.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.